CN Patent

CN116963725A — 特纳帕诺的口服制剂

Assigned to AstraZeneca AB · Expires 2023-10-27 · 3y expired

What this patent protects

本发明提供了化学稳定且可溶的特纳帕诺的药物片剂制剂，其包含大于约6％重量/重量的双HCl形式的无定形特纳帕诺、酸化剂、抗氧化剂、崩解剂、润滑剂、助流剂、填充剂和速释包衣，其中活性成分的总氯化物含量大于5.82％并且粒径分布D50为约18μm至约22μm。

USPTO Abstract

本发明提供了化学稳定且可溶的特纳帕诺的药物片剂制剂，其包含大于约6％重量/重量的双HCl形式的无定形特纳帕诺、酸化剂、抗氧化剂、崩解剂、润滑剂、助流剂、填充剂和速释包衣，其中活性成分的总氯化物含量大于5.82％并且粒径分布D50为约18μm至约22μm。

Drugs covered by this patent

tenapanor-hydrochloride (TENAPANOR HYDROCHLORIDE)

Patent Metadata

Patent number: CN116963725A
Jurisdiction: CN
Classification: —
Expires: 2023-10-27
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.